Loading…
← CockpitCompetitor Analysis › BLSM BlossomHill Therapeutics, Inc.Open in the cockpit ↗

BlossomHill Therapeutics, Inc.BLSMCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Mkt cap
$464M
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$2.67M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.2%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$14.59
1D-3.6%
1W-9.5%
1M+1.3%
3M-7.7%
6Mn/a
YTDn/a
1Yn/a
ATR %12.4%
52w lowhigh47.9% off high

What BlossomHill Therapeutics does

Employees: 63

BlossomHill Therapeutics at a glance

Size BlossomHill Therapeutics (BLSM) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $464M, the 2734th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.59 on 18 Nov 2026.

Short interest Short interest is 1.9% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

BlossomHill Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a-$441,000-$350,000
EBITDAn/a-$63.6M-$36.1M
Net incomen/a-$60.6M-$30.7M
Free cash flown/a-$48.0M-$31.5M
Capital expendituren/a$1.07M$92,000
Total debt$23.1M$279M$173M

Quarterly statements and history in the cockpit →

BlossomHill Therapeutics competitors and peer comparison

How BlossomHill Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BlossomHill Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureBLSMPeer medianRank in peer set
1-month return+1.3%-3.8%8th highest of 21
Distance from 52-week high-47.9%-32.0%5th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%10.8×44.1%+1.0%
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%7.2×n/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%8.8×n/an/a
Evolus EOLSUnited States$468M+7%+14%-5%1.8×n/an/a
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%16.6×24.8%+126.7%
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%2.2×n/an/a
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
Gufic Biosciences GUFICBIO.NSIndia$452M+48%+17%14%4.3×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Pulike Biological Engineering 603566.SSChina$449M-21%-9%5%2.4×4.5%+3.3%
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Dong-A Socio 000640.KSSouth Korea$447M-8%+11%7%0.7×-6.6%+12.8%
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
Zhejiang Chengyi Pharmaceutical 603811.SSChina$445M-21%+5%19%3.4×1.3%+1.3%
RPG Life Sciences RPGLIFE.NSIndia$443M+10%+15%17%5.3×n/an/a

Questions

Which companies are BlossomHill Therapeutics's closest peers?
The cockpit's peer set: Hainan Shuangcheng Pharmaceuticals (002693.SZ), Kwality Pharmaceuticals (KPL.NS), Capricor Therapeutics (CAPR), Zhejiang Yatai Pharmaceutical (002370.SZ), Evolus (EOLS), Handa Pharmaceuticals (6620.TWO), Assembly Biosciences (ASMB), ChengDa PharmaCeuticals (301201.SZ).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.